Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Beaten Down Stocks to Buy According to Hedge Funds. On October 10, Citi lifted the price target on the company’s stock to $48 from $47, while keeping a “Neutral” rating on the stock, as reported by The Fly. Notably, the firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of the Q3 earnings preview. As per the analyst, the group remains well-placed into H2 2025 and 2026 as policy overhangs ease and investor emphasis gets back to fundamentals.

Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock

Elsewhere, Bristol-Myers Squibb Company (NYSE:BMY) and Orbital Therapeutics announced a definitive agreement under which the former will acquire Orbital. The acquisition consists of Orbital’s lead RNA immunotherapy preclinical candidate, currently in IND-enabling studies, OTX-201. Also, Bristol-Myers Squibb Company (NYSE:BMY) would acquire Orbital’s proprietary RNA platform, which integrates circular and linear RNA engineering, advanced LNP delivery, and AI-driven design in a bid to enable durable, programmable RNA therapies tailored to the distinct biology of the diseases.

While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.